Low Serum Albumin Predicts Severe Outcomes in COVID-19 Infection: A Single-Center Retrospective Case-Control Study.

Autor:	Acharya R; Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Poudel D; Department of Rheumatology, Indiana Regional Medical Center, Indiana, PA 15701, USA., Bowers R; Department of Pharmacy, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Patel A; Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Schultz E; Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Bourgeois M; Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Paswan R; Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Stockholm S; Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Batten M; Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Kafle S; RN-BSN Program, Fayetteville State University, Fayetteville, NC 28301, USA., Lonial K; Department of Pulmonology and Critical Care, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA., Locklear I; Department of Pulmonology and Critical Care, Cape Fear Valley Medical Center, Fayetteville, NC 28304, USA.
Jazyk:	angličtina
Zdroj:	Journal of clinical medicine research [J Clin Med Res] 2021 May; Vol. 13 (5), pp. 258-267. Date of Electronic Publication: 2021 May 25.
DOI:	10.14740/jocmr4507
Abstrakt:	Background: Coronavirus disease 2019 (COVID-19) can cause serious complications such as multiorgan failure and death which are difficult to predict. We conducted this retrospective case-control observational study with the hypothesis that low serum albumin at presentation can predict serious outcomes in COVID-19 infection. Methods: We included severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed, hospitalized patients from March to July 2020 in a tertiary care hospital in the USA. Patients were followed for 21 days for the development of the primary endpoint defined as the composite outcome which included acute encephalopathy, acute kidney injury, the requirement of new renal replacement therapy, acute hypercoagulability, acute circulatory failure, new-onset heart failure, acute cardiac injury, acute arrhythmia, acute respiratory distress syndrome (ARDS), high flow oxygen support, intensive care unit (ICU) stay, mechanical ventilation or death; and the secondary endpoint of death only. Univariate and multivariate logistic regression analyses were performed to study the effect of albumin level and outcomes. Results: The mean age was 56.76 years vs. 55.67 years (P = 0.68) in the normal albumin vs. the low albumin group. We noticed an inverse relationship between serum albumin at presentation and serious outcomes. The low albumin group had a higher composite outcome (93.88% vs. 6.12%, P < 0.05) and higher mortality (13.87% vs. 2.38%, P < 0.05) in comparison to the normal albumin group. The multivariate logistic regression analysis revealed higher odds of having composite outcomes with lower albumin group (odds ratio (OR) 10.88, 95% confidence interval (CI) 4.74 - 24.97, P < 0.05). In the subgroup analysis, the multivariate logistic regression analysis revealed higher odds of having composite outcomes with the very low albumin group (OR 7.94, 95% CI 1.70 - 37.14, P < 0.05). Conclusions: Low serum albumin on presentation in COVID-19 infection is associated with serious outcomes not limited to mortality. The therapeutic option of albumin infusion should be investigated. Competing Interests: None to declare. (Copyright 2021, Acharya et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu